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Abstract: Inﬂ  uenza viruses cause respiratory tract infections that in patients with underlying lung 
diseases such as chronic obstructive pulmonary disease (COPD) are associated with exacerbations 
and excess morbidity and mortality. Typically, inﬂ  uenza B is associated with relatively mild, lo-
cal outbreaks, whereas inﬂ  uenza A is the cause of world-wide pandemics. Upon infection, two 
antigens present on the viral surface, hemagglutinin and neuraminidase result in human immunity, 
but since many subtypes of these antigens exist that vary over time, immunity in the population is 
blunted. Vaccination is advocated in high-risk groups including patients with underlying (lung) 
diseases and in the elderly, and needs to be repeated annually with vaccines expected to cover the 
expected change in viral antigenicity. When started early, antiviral drugs, especially neuramini-
dase-inhibitors can be prescribed in adjunct to nonspeciﬁ  c interventions in an attempt to shorten 
disease duration and to prevent complications in case of an inﬂ  uenza infection. Currently, the 
effectiveness of antiviral drugs speciﬁ  cally in patients with COPD has not been proven.
Keywords: inﬂ  uenza, chronic obstructive pulmonary disease, COPD, neuraminidase inhibitors, 
prevention, treatment
Introduction
It is believed that the risk of a pandemic outbreak of inﬂ  uenza is growing. Three pan-
demics occurred in the 20th century; most recently in 1968 which resulted in millions 
of deaths worldwide. A new outbreak may have similar devastating results and is likely 
to affect elderly people, patients with reduced immunity, and patients suffering from 
chronic diseases such as chronic obstructive pulmonary disease (COPD).
Chronic obstructive pulmonary disease is characterized by largely irreversible 
progressive airﬂ  ow limitation. This airﬂ  ow obstruction is associated with an inﬂ  am-
matory process in the bronchial mucosa. Most patients are current or ex-smokers. 
Many patients have one or more exacerbations per year, which are associated with 
an accelerated decline in lung function and decreased quality of life (NHLBI 2006). 
Exacerbations are responsible for over half of the direct disease-related costs of care. 
Viral infections including inﬂ  uenza, respiratory syncytial virus (RSV), and many other 
viruses are important causes of exacerbations, excess morbidity and mortality in COPD 
(Wedzicha 2004; Wilkinson et al 2006). During seasonal outbreaks of viral infections, 
patients with COPD are at risk for respiratory illness-related hospitalizations, irrespec-
tive of age or disease severity (Gorse et al 2006). Prevention and early treatment of 
exacerbations are therefore believed to be an important target in the management of 
COPD. Inhaled steroids may reduce the number and the severity of exacerbations in 
patients with severe airﬂ  ow obstruction and frequent exacerbations, but the effects 
are limited (Burge et al 2000; Jones 2004). Inhaled bronchodilators may have similar 
effects. Annual inﬂ  uenza vaccination is recommended in most COPD guidelines and 
neuraminidase inhibitors are available for the treatment of inﬂ  uenza.International Journal of COPD 2007:2(1) 6
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Evidence of the role of inﬂ  uenza viruses in the pathogen-
esis of COPD and as a cause of exacerbations is discussed 
in this review and current recommendations for prevention 
and treatment of inﬂ  uenza in patients with COPD are sum-
marized.
Inﬂ  uenza viruses
The inﬂ  uenza virus belongs to the orthomyxovirus group. The 
inﬂ  uenza virus is a spherical or ﬁ  lamentous enveloped virus. 
Virus strains are characterized by different hemagglutinin (H) 
and neuraminidase (N) subclasses. Hemagglutinin, a surface 
glycopeptide, aids attachment of the virus at speciﬁ  c receptor 
sites on the walls of susceptible host cells and facilitates entry 
of viruses into the cell. The enzyme neuraminidase facilitates 
cell penetration by pinocytosis and stimulates the release of 
viruses from the host cell by budding through the cell membrane 
(Matrosovich et al 2004). The virus exists in two main forms: 
A and B. Inﬂ  uenza A is generally responsible for epidemics 
and pandemics. Inﬂ  uenza B causes milder, generally more 
localized and less severe outbreaks, eg, in schools or in camps. 
A lesser known C form rarely causes disease in humans. 15 H 
subtypes (H1–H15) and nine N subtypes (N1–N9) have been 
identiﬁ  ed for inﬂ  uenza A viruses. New antigenic variants of 
inﬂ  uenza A develop at irregular intervals through the process 
of antigenic shift, whereas point mutations in inﬂ  uenza A and 
B viruses result in changes in amino acids in the H and the N 
glycoproteins responsible for humoral immunity, resulting 
in antigenic drift (Zambon 1999). These changes render the 
individual’s immune response less able to combat new variants. 
As a result, major shifts in antigenic proﬁ  les of the viruses can 
cause epidemics. The immune system is less blunted by the 
minor antigenic drifts that cause less severe outbreaks (Stam-
boulian et al 2000). In 1957 the appearance of inﬂ  uenza A2 
type H2–N2 was associated with over 20 million deaths. The 
worldwide pandemic that occurred in 1968 was the result of the 
emergence in Hong Kong of inﬂ  uenza H3–N2. Minor antigenic 
drifts have since then caused smaller outbreaks in various areas 
of the world. Avian ﬂ  u, caused by H5–N1, has emerged in 1997 
and re-emerged in 2004–2005 and represents a major change 
in viral surface antigens, and transmission to humans has been 
shown to be a serious threat (Beigel et al 2005).
Inﬂ  uenza infections
Inﬂ  uenza is thought to occur in approximately 20% of the 
world’s population annually. In most cases inﬂ  uenza is 
an acute febrile respiratory disease that occurs in annual 
outbreaks of varying severity. The incubation period of 
inﬂ  uenza is 1 to 3 days. Inﬂ  uenza typically causes exten-
sive destruction of airway epithelial cells (Hers 1966). 
Symptoms start abruptly and consist of fever, shivering, and 
diffuse pains in the extremities. Many patients present with 
early, prominent systemic symptoms and have headache, 
soreness of the throat, and dry cough that can persist for 
several weeks (Monto et al 2000). Mortality can be high in 
the elderly especially in patients with chronic respiratory 
or cardiac diseases. Recovery can take up to 3 months and 
secondary bacterial infections are common, particularly with 
Streptococcus pneumoniae and Haemophilus inﬂ  uenzae. 
Staphylococcus aureus superinfections can cause pneumonia 
that has a mortality of up to 20% (Brundage 2006). 
In otherwise healthy individuals, treatment consists of 
paracetamol, bed rest, and sufﬁ  cient oral intake of ﬂ  uids 
(Wiselka 1994). In patients with COPD, as in patients with 
heart or kidney diseases, early treatment with appropriate 
antibiotics is recommended (Nathan et al 2001).
Role of inﬂ  uenza in stable COPD 
and in exacerbations
In susceptible persons, usually smokers, exposure to inhaled 
noxious particles and gases results in inﬂ  ammation in the 
bronchial mucosa, lung parenchyma, and pulmonary vascu-
lature (NHLBI 2006). Other processes believed to be of im-
portance are an imbalance of proteinases and antiproteinases 
and oxidative stress. Many cells and mediators are involved 
in the pathogenesis of inﬂ  ammation in COPD. With time this 
inﬂ  ammation can result in structural changes in the bronchial 
wall and destruction of lung parenchyma or emphysema, 
and consequently in irreversible airﬂ  ow obstruction and gas 
exchange abnormalities. Host factors are believed to be im-
portant in the pathogenesis of the characteristic inﬂ  ammation 
in COPD, as are viruses (Proud and Chung-Wai 2006). Also, 
host behavior in response to viruses and possible aberrant 
antiviral host responses may inﬂ  uence the persistence of 
inﬂ  ammation following exposure to viruses. In stable COPD 
latent respiratory viruses, such as RSV or adenoviruses have 
been associated with accelerated lung function decline, in-
dependent of smoking status, exacerbation frequency, and 
lower airway bacterial load (Mallia and Johnston 2006). 
RSV may also be associated with systemic inﬂ  ammation. 
Whether other viruses, such as different inﬂ  uenza strains, 
have similar effects in stable COPD is at present unknown. 
It has been shown that respiratory viruses, such as RSV and 
also inﬂ  uenza viruses, enter into the bronchial epithelial cells 
where they can replicate and result in epithelial cell destruc-International Journal of COPD 2007:2(1) 7
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tion and necrosis. This results in increased permeability of 
the mucosa, which allows other pathogens and irritants to 
penetrate, leads to neurogenic inﬂ  ammation by substance 
P and bradykinin, M2- and β2-receptor dysfunction, and 
contributes to bronchial hyperresponsiveness (Wilkinson 
et al 2006). Airway hyperresponsiveness causes excessive 
airway narrowing in COPD patients.
Viruses are not only involved in the inﬂ  ammation of 
stable COPD, but they also can trigger exacerbations (Rohde 
et al 2003; Wedzicha 2004). Exacerbations are commonly 
deﬁ  ned as events in the natural course of the disease charac-
terized by a change in the patient’s baseline dyspnea, cough 
and/or sputum that is beyond normal day-to-day variation, is 
acute in onset, and may warrant a change in regular medica-
tion in patients with underlying COPD (NHLBI 2006).
Respiratory viruses are considered to be amongst the 
most important triggers of exacerbations. Between 15% and 
up to 64% of COPD exacerbations have been found to be 
associated with symptomatic colds precipitated by viruses 
(Seemungal et al 2001; Wedzicha 2004). Of these, rhinovirus 
and enteroviruses, both belonging to the picornavirus group 
of RNA viruses, stand out. Coronavirus, adenovirus, RSV, 
Inﬂ  uenza A and B, and parainﬂ  uenza viruses have been 
linked with COPD exacerbations and often multiple viruses 
can be detected (Rohde et al 2003). Various mechanisms are 
believed to be involved in the way viruses induce or aggravate 
exacerbations. Rhinoviruses attach to airway epithelium cells 
through intercellular adhesion molecule-1 (ICAM-1) and 
thereby cause inﬂ  ammatory cell recruitment and activation. 
Also, viral infections were found to be associated with in-
creased oxidant stress, the activation of nuclear factor κB, and 
the expression of stress-response genes (Wedzicha 2004).
The proportion of exacerbations related to isolation 
of inﬂ  uenza virus differs between studies and is probably 
inﬂ  uenced by the number of COPD patients that receive 
inﬂ  uenza vaccination (Gorse et al 2006). Inﬂ  uenza infections 
are cause of excess morbidity and mortality in COPD and 
may affect the progression of the disease. In older studies 
and in populations that received no inﬂ  uenza vaccination, 
the hospitalization rates for acute exacerbations of COPD 
are substantially higher in the inﬂ  uenza season than in the 
noninﬂ  uenza season (Simonsen et al 2000). 
Inﬂ  uenza vaccination in COPD 
patients
Considering the inﬂ  uence of different respiratory viruses 
in stable COPD and the important role of viral infections 
in exacerbations, vaccination is a potentially effective way 
to reduce morbidity and mortality caused by exacerbations. 
Unfortunately, signiﬁ  cant variation within the major virus 
types causing disease limits the success of vaccination pro-
grammes. Since inﬂ  uenza viruses display antigenic shift and 
drift, new vaccines must be developed at regular intervals. In 
response to the arrival of new pandemic strains, new vaccines 
must be made available in sufﬁ  cient quantities. The effec-
tiveness of the vaccines, usually inactivated virus vaccines 
containing 3 virus strains (2 type A and 1 type B) depends on 
the similarity between the strains in the vaccine and the virus 
strains likely to circulate in the upcoming winter. Protection 
occurs through circulating antibodies to H and N or stimula-
tion of cytotoxic T-cell responses. Protection by inﬂ  uenza 
vaccination is only effective in 70% of patients and only lasts 
for one year (WHO 2005). New vaccines must be prepared 
each year to cover the expected change in antigenicity. As a 
consequence, by deﬁ  nition supplies are limited in case of an 
emerging epidemic. Obviously, the beneﬁ  t of vaccination is 
largest in epidemic years when the vaccine strain is similar 
to the epidemic strain.
Currently, all standards and guidelines therefore rec-
ommend annual inﬂ  uenza vaccination in all patients with 
COPD as a cost-effective intervention, in spite of the fact 
that there are no randomized studies of inﬂ  uenza vaccinations 
in patients with COPD (NHLBI 2006). 
Evidence to support this recommendation largely stems 
from observational studies in elderly subjects. In a large cohort 
study of nearly 150,000 elderly patients, vaccination resulted 
in a reduction of 32% in the numbers of hospitalizations for 
all respiratory conditions and a reduction of about 50% in 
all-cause mortality compared with nonvaccinated subjects 
(Nichol et al 1999). In subjects with chronic lung diseases, 
vaccination resulted in a 52% reduction in hospitalizations 
and a 70% decrease in death rates during inﬂ  uenza seasons 
(Nichol et al 1999). A meta-analysis of published effects 
of inﬂ  uenza vaccination by Gross and colleagues (1995) 
showed a 56% reduction in respiratory illnesses, a 50% 
reduction in hospitalizations, a 68% reduction in all cause 
deaths, and a 53% reduction in pneumonia in vaccinated 
subjects. In a randomized clinical trial, Wongsurakiat and 
colleagues (2004) demonstrated that inﬂ  uenza vaccination is 
highly effective in the prevention of acute respiratory illness 
related to inﬂ  uenza virus infection, regardless of severity of 
COPD, comorbid diseases, age, gender, or smoking status.
From their extensive review of the literature and the 
limited number of studies speciﬁ  cally performed in COPD 
patients, published in the format of a Cochrane review, Poole International Journal of COPD 2007:2(1) 8
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and colleagues (2006) concluded that administration of an 
inactivated inﬂ  uenza vaccination has a clinically important 
and signiﬁ  cant effect in  reducing exacerbations, caused by 
inﬂ  uenza, occurring three or more weeks after vaccination, and 
probably an effect on the total number of exacerbations in COPD 
patients. In epidemic years, when the proportion of exacerbations 
caused by inﬂ  uenza is higher, this effect is likely to be greater. 
Only limited data on the effects of inﬂ  uenza vaccination on 
number or duration of hospitalizations, mortality, or outcomes 
in terms of lung function have been reported.
They also concluded that there was no evidence of an 
increase in early exacerbations (Poole et al 2006). Yet, in 
the experience of many clinicians, transient increases in 
symptoms may occur in the weeks after vaccination.
Treatment of inﬂ  uenza in patients 
with COPD
Chronic obstructive pulmonary disease patients are susceptible 
to unfavorable outcomes in case of an inﬂ  uenza infection. 
Vaccination can help prevent exacerbations, pneumonia, and 
hospitalization in such patients, but the effects are limited 
to a certain extent by less than ideal immunization rates and 
antigenic shifts that decrease the effectiveness of the vaccine. 
Exacerbations that occur as a result of an inﬂ  uenza virus 
infection should be treated with inhaled bronchodilators, 
systemic corticosteroids, and antibiotics aimed at suspected 
bacterial superinfections and low-flow oxygen when 
appropriate. Other nonspeciﬁ  c measures such as sufﬁ  cient ﬂ  uid 
intake, bed-rest, antipyretic drugs, and/or cool mist humidiﬁ  ers 
are recommended as they are in otherwise healthy adults.
Four drugs are currently available for the prophylaxis 
or treatment of influenza infections: amantadines 
(amantadine and rimantadine) and N-inhibitors (zanamivir 
and oseltamivir). The amantadines inhibit viral uncoating 
inside host cells. They are effective against influenza A 
only, and the effects are limited because of the emergence 
of resistant strains. Also, they have several toxic 
side-effects that further reduce their usefulness (Jefferson 
et al 2006). N-inhibitors are effective against all N-
subtypes and therefore, other than amantadines, they 
can be used against all strains of influenza. They act by 
preventing the release of virions from infected host cells. 
Generally it is recommended not to use N-inhibitors 
routinely for seasonal influenza and use these drugs only 
with associated public-health measures in a pandemic 
situation (Moscona 2005). Furthermore, both drugs have 
no significant effect on asymptomatic influenza.
Neuraminidase-inhibitors have been tested in various 
scenarios, but no studies speciﬁ  cally performed in COPD 
patients are currently available. Published prophylaxis and 
treatment trials suggest that both zanamivir and oseltamivir 
are effective in preventing and treating the symptoms and 
complications of inﬂ  uenza infection but that they do not 
prevent the infection in itself and will not prevent voidance 
of viruses from the nose. The literature regarding the ef-
fects of N-inhibitors for preventing and treating inﬂ  uenza in 
healthy adults has recently been reviewed by Jefferson and 
colleagues (2006). This excellent review summarizes the 
result of 52 randomized controlled trials testing N-inhibitors 
in controlled clinical prophylaxis, post-exposure prophylaxis, 
and treatment trials. They conclude that oseltamivir in a 
daily oral dose of 75 mg and of inhaled zanamivir 10 mg 
daily have no effect in prophylaxis of inﬂ  uenza-like illness 
compared with placebo. Whether higher doses are more ef-
fective is uncertain. The efﬁ  cacy of oseltamivir compared 
with placebo, orally administered in a dose of 75 mg daily, 
against symptomatic inﬂ  uenza is 61%. In a dose of 150 mg 
daily, the efﬁ  cacy is 73% (Jefferson et al 2006). 
These authors argue against the use of these drugs in 
routine seasonal inﬂ  uenza control.
In general N-inhibitors have low effectiveness, high ef-
ﬁ  cacy, and appear well-tolerated. The possibility of emerging 
resistance has been put forward. With oseltamivir, resistance 
has been reported to be around 0.4% (Zambon and Hayden 
2001; Monto et al 2006). 
In households, the transmission of seasonal inﬂ  uenza has 
been shown to be interrupted (Welliver et al 2001). 
Neuraminidase inhibitors are recommended for the 
treatment of at-risk patients who present with inﬂ  uenza-like 
illness and who can start within 48 hours of the onset of symp-
toms. Ideally treatment is started earlier, preferably within 12 
hours after the onset of symptoms (Aoki et al 2003).
Currently, no controlled studies on the effectiveness and 
the safety of N-inhibitors speciﬁ  cally for COPD patients 
or patients with other underlying respiratory disease are 
available. From observational studies it is concluded that 
N-inhibitors can be used in addition to inﬂ  uenza vaccination 
in patients with disorders of the respiratory system including 
COPD, who are at high-risk of developing inﬂ  uenza related 
complications (Gorse et al 2006; Williamson and Pegram 
2002). Under these conditions they can affect respiratory 
complications such as pneumonia or bronchitis. 
At present no robust data are available to support the 
use of N-inhibitors in avian inﬂ  uenza (Jefferson et al 2006). 
Oseltamivir has been used in an uncontrolled setting but data International Journal of COPD 2007:2(1) 9
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regarding the effectiveness does not allow for reaching a ﬁ  rm 
conclusion (Leneva et al 2000).
Unlike the older antiviral drugs, amantadine and riman-
tadine, N-inhibitors rarely cause central nervous system 
adverse effects, yet these drugs may have side-effects. Zana-
mivir has been shown to cause bronchospasm in susceptible 
patients and should be used with caution in COPD-patients 
(Freund et al 1999). Patients prescribed zanamivir should 
have fast-acting bronchodilators available. Other side effects 
of zanamivir include diarrhea, whereas oseltamivir has been 
shown to be able to cause nausea, vomiting, and retching 
(Nicholson et al 2000). 
Conclusion
Inﬂ  uenza viruses have been shown to be involved in the 
pathophysiology of COPD, both in stable disease and in 
exacerbations. Annual inﬂ  uenza vaccinations are recom-
mended for all patients and have been proven effective 
in all but a few cases. Vaccination remains the gold stan-
dard for the prevention of inﬂ  uenza in at-risk subjects, 
including patients with chronic diseases such as COPD. 
Recommended treatment of inﬂ  uenza in COPD patients 
includes the regular nonspeciﬁ  c measures that are gener-
ally believed to be helpful in all patients. When used early, 
preferably within 12 hours after the onset of symptoms, 
the N-inhibitors, zanamivir and oseltamivir, are useful 
adjuncts to vaccination for the management of patients at 
risk of developing inﬂ  uenza related complications, such as 
COPD patients. N-inhibitors should not be used in routine 
seasonal inﬂ  uenza control, not even in patients with COPD. 
In a serious epidemic or pandemic their use is recommended 
in conjunction with other public health measures, in COPD 
patients and others alike.
References
Aoki FY, Macleod MD, Paggiaro P, et al. 2003. Early administration of 
oseltamivir increases the beneﬁ  t of inﬂ  uenza treatment. J Antimicrob 
Chemother, 51:123–9.
Beigel JH, Farrar J, Han AM, et al. 2005. Avian inﬂ  uenza A (H5N1) infec-
tion in humans. N Eng J Med, 353:1374–85.
Brundage LF. 2006. Interactions between inﬂ  uenza and bacterial respira-
tory pathogens: implications for pandemic preparedness. Lancet Infect 
Dis, 6:303–12.
Burge PS, Calverley PMA, Jones PW, et al. 2000. Randomised, double 
blind, placebo controlled study of ﬂ  uticasone propionate in patients 
with moderate to severe chronic obstructive pulmonary disease: the 
ISOLDE trial. BMJ, 320:1297–303.
Freund B, Gravenstein S, Elliott M, et al. 1999. Zanamivir: a review of 
clinical safety. Drug Saf, 21:267–81.
Gorse GJ, O’Connor TZ, Young SL, et al. 2006. Impact of a winter respira-
tory virus season on patients with COPD and association with inﬂ  uenza 
vaccination. Chest, 130:1109–16.
Gross PA, Hermogenes AW, Sacks HS, et al. 1995. The efﬁ  cacy of inﬂ  uenza 
vaccine in elderly patients. Ann Intern Med, 123:518–23.
Hers JF. 1966. Disturbances of the ciliated epithelium due to inﬂ  uenza virus. 
Am Rev Respir Dis, 93(suppl):162–77.
Jefferson TO, Demicheli V, Di Pietrantonj C, et al. 2006. Neuraminidase 
inhibitors for preventing and treating inﬂ  uenza in healthy adults. Co-
chrane Database Syst Rev, 3:CD001265.
Jones PW. 2004. Clinical effects of inhaled corticosteroids in chronic ob-
structive pulmonary disease. Proc Am Thorac Soc, 1:167–70.
Leneva IA, Roberts N, Govorkova EA, et al. 2000. The neuraminidase 
inhibitor GS4104 (oseltamivir phosphate) is effective against A/Hong 
Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) inﬂ  uenza 
viruses. Antiviral Res, 48:101–15.
Mallia P, Johnston SL. 2006. How viral infections cause exacerbations of 
airway diseases. Chest, 130:1203–10.
Matrosovich MN, Matrosovich TY, Gray T, et al. 2004. Neuraminidase is 
important for the initiation of inﬂ  uenza virus infection in human airway 
epithelium. J Virol, 78:12665–7.
Monto AS, Gravenstein S, Elliott M, et al. 2000. Clinical signs and symptoms 
predicting inﬂ  uenza infection. Arch Intern Med, 160:3243–7.
Monto AS, McKimm-Breschkin JL, Macken C, et al. 2006. Detection of 
inﬂ  uenza viruses resistant to neuraminidase inhibitors in global sur-
veillance during the ﬁ  rst three years of their use. Antimicrob Agents 
Chemother, 50:2395–402.
Moscona A. 2005. Neuraminidase inhibitors for inﬂ  uenza. N Eng J Med, 
353:1363–73.
Nathan RA, Geddes D, Woodhead M. 2001. Management of inﬂ  uenza in 
patients with asthma or chronic obstructive pulmonary disease. Ann 
Allergy Asthma Immunol, 87:447–54.
[NHLBI] National Heart, Lung and Blood Institute. 2006. Global strategy 
for the diagnosis, management and prevention of chronic obstructive 
pulmonary disease. NHLBI/WHO workshop report. Updated 2006 
[online]. Accessed on 5 January 2007. URL: http://www.goldcopd.
com. 
Nichol KL, Baken L, Nelson A. 1999. Relation between inﬂ  uenza vaccina-
tion and out-patient visits, hospitalization, and mortality in elderly per-
sons with chronic lung disease. Annals Internal Med, 130:397–403.
Nichol KL, Wuorenma J, von Stenberg T. 1998. Beneﬁ  ts of inﬂ  uenza vac-
cination for low-, intermediate-, and high-risk senior citizens. Arch 
Internal Med, 158:1769–76.
Nicholson KG, Aoki FY, Osterhaus AD, et al. 2000. Efﬁ  cacy and safety of 
oseltamivir in the treatment of acute inﬂ  uenza: a randomised controlled 
trial. Lancet, 355:1845–50.
Poole PJ, Chacko E, Wood-Baker RWB, et al. 2006. Inﬂ  uenza vaccine 
for patients with chronic obstructive pulmonary disease. Cochrane 
Database Syst Rev, 1:CD002733.
Proud D, Chung-Wai C. 2006. Role of viral infections in asthma and 
chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol, 
35:513–18.
Rohde G, Wiethage A, Borg I, et al. 2003. Respiratory viruses in exacerba-
tions of chronic obstructive pulmonary disease requiring hospitaliza-
tions: a case-control study. Thorax, 58:37–42.
Seemungal TA, Harper-Owen R, Bhowmik A, et al. 2001. Respiratory 
viruses, symptoms and inﬂ  ammatory markers in acute exacerbations 
and stable chronic obstructive pulmonary disease. Am J Respir Crit 
Care Med, 164:1618–23.
Simonsen L, Fukuda K, Schonberger LB, et al. 2000. The impact of inﬂ  uenza 
epidemics on hospitalizations. J Infect Dis, 181:831–7.
Stamboulian D, Bonvehi PE, Nacinovich FM, et al. 2000. Inﬂ  uenza. Infect 
Dis Clin North Am, 14:141–66.
Wedzicha JA. 2004. Role of viruses in exacerbations of chronic obstructive 
pulmonary disease. Proc Am Thorac Soc, 1:115–20.
Welliver R, Monto AS, Carewicz O, et al. 2001. Effectiveness of oseltamivir 
in preventing inﬂ  uenza in household contacts: a randomized controlled 
trial. JAMA, 285:748–54.
[WHO] World Health Organisation. 2005. Inﬂ  uenza vaccines: position 
paper. Wkly Epidemiol Rec, 80:279–87.International Journal of COPD 2007:2(1) 10
Wesseling
Wilkinson TMA, Donaldson GC, Johnston SL, et al. 2006. Respiratory 
syncytial virus, airway inﬂ  ammation and FEV1 decline in patients 
with chronic obstructive pulmonary disease. Am J Respir Crit Care 
Med, 173:871–6.
Williamson JC, Pegram PS. 2002. Neuraminidase inhibitors in patients with 
underlying airways disease. Am J Respir Med, 1:85–90.
Wiselka M. 1994. Inﬂ  uenza : diagnosis, management and prophylaxis. 
BMJ, 308:1341–5.
Wongsurakiat P, Maranetra KN, Wasi C, et al. 2004. Acute respiratory illness 
in patients with COPD and the effectiveness of inﬂ  uenza vaccination. 
Chest, 125:2011–20.
Zambon MC, Hayden FG. 2001. Global neuraminidase inhibitor suscep-
tibility network. Position statement: global neuraminidase inhibitor 
susceptibility network. Antiviral Res, 49:147–56.
Zambon MC. 1999. Epidemiology and pathogenesis of inﬂ  uenza. J Anti-
microb Chemother, 44(suppl)B:3–9.